Sept 21 (Reuters) – Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes,
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Priority Technology to go private in $1.6 billion CEO-led deal
Sept 21 (Reuters) - Payments and banking solutions provider Priority Technology Holdings said on Monday…
Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
Sept 21 (Reuters) - The weight-loss drug market is booming, with biotech firms racing to…
Swiss captain Xhaka sidelined over fake COVID certificate
VIDEO SHOWS: FILE FOOTAGE OF SWITZERLAND MIDFIELDER GRANIT XHAKA SHOWS: VANCOUVER, CANADA (JULY 5, 2026)…
